Register Here

Description

Pre-Exposure prophylaxis (PrEP) has been shown to be safe and effective in reducing HIV infection. With recent updates in PrEP, many options are available, and selection of the best regimen is the key to success. The purpose of this webinar is to review the pharmacologic basis for drug dosing and outline gaps and challenges in management.

Learning Objectives

• Review the key pharmacokinetic and pharmacodynamic properties of emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, and cabotegravir
• Identify patients who may be appropriate for Daily vs. Event-Driven PrEP
• Review key side effects of PrEP and potential strategies for management
• Describe the role of adherence on PrEP effectiveness